Amsterdam, the Netherlands – Royal Philips (NYSE: PHG, AEX: PHIA), a global leader in health technology, and Radboud university medical center (Radboudumc), a leading Dutch academic research and teaching hospital (Nijmegen, the Netherlands), have announced the positive results of a clinical study conducted by Radboudumc aimed at setting a new standard of safety and accuracy in the diagnosis of small peripheral lung lesions. The study outcomes represent a promising milestone in the global innovation effort to set a new clinical standard for detecting lung cancer at an early stage, potentially leading to improved prognoses for patients.
Radboudumc’s observational study reported the diagnostic accuracy and procedural radiation dose for patients undergoing an endobronchial lung biopsy supported by Philips Lung Suite - a solution that uses 3D imaging with augmented fluoroscopy to support high precision diagnosis and minimally-invasive therapy in one room. Diagnostic accuracy of 90% was reported while reducing the average total effective radiation dose per procedure by more than half from 47.5 Gy·cm2 (effective dose: 14.3 mSv) to 25.4 Gy·cm2 (effective dose: 5.8 mSv). The median long-axis diameter of the 248 lesions navigated to during the study was 13 mm (range 5-65mm). The results of the study were published in the October 2021 issue of the Journal of Bronchology & Interventional Pulmonology: Volume 28 - Issue 4 .